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between −1 and −2.5), Osteoporosis (T score <−2.5, with presence of fractures).
We used the Wilcoxon/Kruskal Wallis statistical test for analysis.
Results: First, we divided our patients in those with Osteopenia (n = 15) and those
affected by Osteoporosis (n = 6). Mean FEV1 values were signiﬁcantly higher in
patients affected by Osteopenia than in those affected by Osteoporosis (p = 0.05).
We found a positive correlation between BMI and Z score (r = 0.55 p = 0.0097),
suggesting that a good nutritional status affects the value of Z score. We then divided
patients based on pancreatic status. There was a positive correlation between FEV1
and Z score for pancreatic insufﬁciency, while subjects with pancreatic sufﬁciency
and mild clinic expression showed an association between VitD and Z score, which
may reﬂect a low patient’s compliance.
Conclusions: The results of the study on 21 CF patients show that there is a positive
correlation between BMI and bone disease related to CF. Patients with low BMI had
pathologic values of T score and Z score. The correlation between BMI and bone
disease corroborates the idea that nutritional status is an important prognostic factor.
Our ﬁndings emphasize the role of multiple factors in Cystic Fibrosis phenotype
and the importance (especially for young patients) of achieving and maintaining
a good nutritional status, associated to a good therapeutic compliance, in order to
avoid the negative evolution of pulmonary disease and related bone disorders.
Bibliography: Hecker TM, et al. Drugs 2004, 64: 133–147.
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Between November 1996 and December 2006, 64 patients (32 M, mean age
25.6±10 years; 32 F mean age 25.1±6.3 years) with end-stage cystic ﬁbrosis
underwent bilateral sequential lung transplantation.
Before transplantation patients’ airways were colonized by Pseudomonas aerugi-
nosa (52 pts), Staphylococcus aureus (7 pts) and Burkholderia cepacia complex (5
pts).
After transplantation patients were observed at 1, 5, 8 and 10 years, examining the
culture of sputum or bronchoalveolar lavage ﬂuid, the serological test for CMV
and the rate of intravenous therapy following bacterial lower airways respiratory
infections.
Of these 64 pts, 34 (54%) are actually alive. 30 pts (46%) died, but only 4 deaths
(1.2%) were caused by infections: 3 pts died in the early post operative period for
sepsis, 1 pt died 14 months after transplantation for P. carinii infection, probably due
to poor compliance to therapy. Opportunistic infections of the lung with P. carinii
occurred in other 2 pts: both responded to treatment.
Early after transplantation the same germs that were present before the transplan-
tation grew again in the culture of sputum or BAL.
The rate of pts colonized by bacteria was 92% at 12 months, stabilized at 100% at 5,
8 and 10 years. The rate of pts with CMV infection was 74% and 28% respectively at
1 and 5 years, zeroing at 8 and 10 years; in our Center CMV infections were treated
in preclinical stage, only 1 pt developed CMV gastric disease, diagnosed by biopsy.
11% of pts had positive sputum or BAL culture for Aspergillus fumigatus during
the ﬁrst year, 7% of pts at 5 years and 22% at 8 years. 2 pts with bronchiolitis
obliterans syndrome had evidence of pulmonary aspergillosis at autopsy and 1 pt
had A. fumigatus infection of the right bronchial anastomosis.
3 pts with B. cepacia colonization who survived the early post operative period did
not have a higher infections rate or a worse outcome than pts not colonized by the
germ.
The rate of intravenous therapy following bacterial respiratory infections was 5%,
20%, 44% respectively at 1, 5, 8 and 10 years after transplantation.
In conclusion, high risk periods for developing infections are the 1st year post
transplantation, when immunosuppressive regimen is intensive, and from 5th year
on, because of the reinduction immunosuppressive therapy after BOS.
In these pts meticulous follow-up, prompt recognition and treatment of pulmonary
infections are essential to prevent poor outcomes.
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Case Report: GG, 37-year-old woman, complete form of CF (genotype
F508del/G542X), stable clinical and nutritional trend (BMI 18%, FEV1 42%).
Chronic colonization by Pseudomonas, frequently haemoptysis, subjected to
bronchial ADA for three times. Ursodeoxycolic acid therapy for chronic liver
disease and asymptomatic cholelithiasis.
In July 2006, a sudden abdominal pain appears to the right upper quadrant.
Physical examination shows a treatable abdomen, pain occurs by hard tapping at
the right upper quadrant, moderate hepatomegaly. Plain abdominal X-Ray: normal;
laboratory tests: moderate microcytic hypochromic anemia.
Ultrasound shows a roundish mass in VII-VIII segment of the liver, 6× 5 cm in di-
ameter, dishomogeneous with central liquiﬁed area. The abdominal CT conﬁrms the
presence of roundish formation with diameter 5.6 cm, hypodense in basal condition
with central zone of colliquation (Abscess? New formation of colliquation?).
Due to diagnostic antibody-titer for Enthamoeba Histolytica (1:120) and detection
of trophozoites in the drainage liquid, the patient starts therapy with Metronidazole
and Dehydroemetine.
Abdomen MRI: conﬁrms previous CT report. In January 2007, because of deterio-
ration of general condition, a colonoscopy is carried out that shows a big blackish
vegetating mass; this is easily bleeding with the size about 5 cm, ascribable to the
intestinal location of amoebic formation. Later, an adenocarcinoma was diagnosed
based on histological examination.
In February 2007, the patient undergoes operation of right hepatectomy (resection
of three lesions in IVa, IVb and III segments) and right hemicolectomy. After
operation, pleuric effusion solves after drain. One month later, she starts antiblastic
drug therapy.
At a distance of 8 months the patient is treated by 6 cycles of chemotherapy that
she tolerates well, with a progressive improvement in general condition.
CF is a chronic pathology which causes an increase in risk of developing some
pathologies, such as colon carcinoma with a 6.4 RR.
GI symptoms, particularly if they are persistent or uncountable, have to be always
carefully monitored, with particular attention to increased preponderance of GI
tumours in patients with CF.
Reference(s)
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In Cystic Fibrosis (CF) patients azithromycin (AZM) in multiple trials has demon-
strated to improve lung function, but there is a large variability in study design,
dosage and outcome measures among these trials. Moreover, long-term studies on
chronic effects of AZM are scanty.
The aim of the study was to evaluate the changes in pulmonary function and
nutritional status in CF patients over 12 months of AZM treatment.
We retrospectively collected the data of 50 patients on daily 250mg AZM contin-
uous therapy; out of these we examined the data of 25 subjects (males 9, mean
age 25.2, range 8−56 years, 50% chronically infected by Pseudomonas aeruginosa)
who concluded a period of 12 months of treatment.
At the baseline and every 3 months we analyzed the changes of BMI, CV, FEV1





3 6 9 12
BMI 19.8±3 20.2±3.2 20.4±2.8 20.5±3.1 20.4±3.0
CV 79.1±20.2 82.7±19.1 86.6±18.9 85.9±18.2 80.6±19.6
FEV1 61.0±20.7 63.6±17.8 66.3±16.3 66.4±15.6 63.7±21.2
FEF25−75 32.5±22.9 33.9±20.9 34.6±22.3 34.4±19.2 36.4±27.3
The table shows the mean values (+ SD) of BMI, CV, FEV1 and FEF 25−75 at
baseline, 3, 6, 9, 12 months of treatment. The trends are statistically signiﬁcant for
both BMI (p< 0.01) and CV (p< 0.02), but not for FEV1 and FEF25/75.
Our results show that AZM long-term treatment may improve the nutritional status
and respiratory function in CF patients. In addition, the improvement reached after
3 months remains stable throughout the whole year of treatment.
